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ABSTRACT
This study was designed to test the hypothesis that vasodilator drugs can enhance selective
heating of solid tumors by producing a favorable redistribution of blood flow between tumor and
normal tissues. Subcutaneous transmissible venereal tumor implants were heated by inductive
diathermy using Helmholtz coils in 8 dogs. The temperature rise in tumor and adjacent muscle
was measured before and after giving hydralazine (0.5 mg/kg i.v.). Blood flow to the tumors and
underlying muscle was measured with radioactive tracer microspheres. Before hydralazine
treatment mean muscle blood flow was about one-third tumor blood flow (0.11  0.02 vs. 0.28 
0.09 ml/min/g), and tumor and normal muscle temperatures were not significantly different (40.0
 0.6 vs. 39.7  0.l oC). After hydralazine tumor blood flow decreased and muscle blood flow
increased in every dog, and selective heating of the tumors became possible. Muscle blood flow
averaged 0.67  0.13 ml/min/g, 17 times greater than tumor blood flow, which decreased to 0.04
0.02 ml/min/g. Core tumor temperature was 48.0  0.9 vs. 38.5  0.5 o C for underlying muscle.
Blood pressure was maintained at 80  5.7 mmHg. These results demonstrate that adjuvant
treatment with vasodilators is a promising technique to increase the temperature difference
between tumors and surrounding normal tissues during local heat therapy.
Key words: blood flow, heat, hyperthermia, regression, therapeutic ratio, treatment, tumor
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INTRODUCTION
Local hyperthermia therapy for cancer involves the application of microwaves, radiofrequency
current, or high intensity ultrasound to warm only the tumor-bearing region while core body
temperature is maintained near 37°C. Such local heat treatment is now being tested clinically at
several institutions with encouraging, but not uniformly successful, results [1-7]. The goal of
local heat therapy is to raise the temperature of the tumor mass to a lethal leve1 [8-10] without
damaging surrounding normal tissue. Ideally, the temperature of the entire tumor would be raised
to cytotoxic levels, which drop abruptly at the tumor edge to levels not damaging to normal
tissues.
In practice, the tissue temperatures actually attained depend on the balance between the rate of
heat deposition and the rate of heat removal from the tissues [l0, 11]. The results of animal
experiments [12] and computer modeling [10, 11] clearly show that blood perfusion is the
primary mechanism for heat removal from tissue volumes greater than a few cubic centimeters.
Hence, many authorities now believe that the relatively low blood flow found in certain tumors
as compared to surrounding normal tissue explains the selective heating of tumor tissue often
observed during local hyperthermia [1-3, 10, 13-15]. Presumably, such blood flow differences
are the result of functional differences between tumor and normal microvasculature.
Tumor vessels are typically enlarged, elongated capillaries without smooth muscle, which
remain maximally dilated at all times [16-18]. As a result, tumor vasculature presents a fixed
resistance to blood flow. In contrast, normal arterioles in adjacent tissues maintain a high degree
of autoregulatory control over local blood flow and are capable of responding to heat and
metabolic alterations, as wel1 as to vasoactive drugs. We hypothesized, therefore, that this
difference in the responsiveness of tumor and normal vasculature can be manipulated to produce
selective temperature elevation in a tumor during local heat therapy [19, 20]. Specifically,
pretreatment of a patient with a direct-acting vasodilator drug would be expected to lower
vascular resistance in normal tissues, increasing perfusion in them, while simultaneously
shunting blood flow away from the tumor. Such effects have, in fact, been described in
experimental animals for the vasodilators isoproterenol, chlorpromazine, amyl nitrate [21] and
prostaglandin E2 [22]; and in human patients for the vasodilator prostaglandin El [23].
Accordingly, we performed the following study to determine the effect of the direct acting
vasodilator, hydralazine, on the distribution of blood flow and the temperature rise in tumor and
adjacent normal tissue during local heat therapy. We studied the canine transmissible venereal
tumor because its size and geometry approximate those of human tumors.
MATERIALS AND METHODS
Transplantation of the canine transmissible venereal tumor (TVT)
Serial transplantation was performed by subcutaneous injection of single-cel1 suspension
prepared by trypsinization of primary tumors according to the methods of Epstein and Bennett
[24] and Cohen [25]. Each dog received an inoculation (2-4 x 108 cells) in the media1 aspect of
2

the upper hindlimb. At the time of the experiment, tumor weight ranged from 22 to 100 grams
(mean, 55 g) after a growing period of 41-110 days (mean, 56 days).
Animal preparation and thermometry
Eight tumor-bearing mongrel dogs weighing 7.0-19.5 kg were used. Anesthesia was induced
with thiopental sodium and maintained by methoxyfluorane, nitrous oxide, and oxygen
inhalation. Dogs were placed in dorsal recumbency on a V-shaped animal board. Catheters were
placed in the left ventricle for injection of radioactive tracer microspheres to measure blood flow;
in the right brachial artery for withdrawal of reference blood samples; in the left brachial artery
for monitoring blood pressure; and in a brachial vein for drug and fluid administration.
Hollow, open-ended plastic cannulae (1 mm diameter) were inserted into the tumor center and
into normal muscle underlying the tumor. These cannulae permitted repeated insertion and
withdrawal of rapidly responding (0.1 sec rise time) hypodermic-style thermistors (Yellow
Springs Instruments Co., Inc., Yellow Springs, OH, U.S.A.) for monitoring tissue temperature.
These temperatures were recorded on a 2-channel rectilinear strip-chart recorder (Houston
Instruments, Houston, TX, U.S.A.). A flexible temperature probe was placed in the esophagus, at
the leve1 of the heart, to monitor core body temperature. Arterial blood pressure and core body
temperature were recorded continuously by a graphic recorder.
Microsphere technique
The use of radioactively labeled tracer microspheres to measure regional blood flow is wellestablished [22, 26, 27]. In this study tracer microspheres (3M Co., Minneapolis, MN, U.S.A.)
with mean diameter of 15  0.9 m were used. Microspheres containing four different -emitting
labels ([141Ce], [ 85Sr], [95Nb] and [46 Sc]) were employed, allowing four blood flow measurements
to be made during the experiment. The microspheres were suspended in 10% dextran. For each
trial a 2.0 ml aliquot of well-mixed suspension containing approximately 10 6 microspheres was
injected into the left ventricle and the catheter was flushed with 10 m1 of 0.9% saline. This
catheter had multiple side-holes to promote homogeneous mixing of the microsphere suspension
with blood.
A reference blood sample was collected from the right brachial artery into a motor-driven
syringe at a constant rate of 7.3 ml/min, starting 10 sec before the injection of microspheres and
continuing for a total of 120 sec. This sample provided a known blood flow into a ‘reference
organ’ for the purpose of calibrating regional blood flow in tissue samples. To determine tissue
perfusion at the end of each experiment, the heated tumor was excised, weighed, and placed in
plastic vials for determining radioactivity. Several samples of underlying muscle tissue were also
taken. Measurement of the radioactivity, in counts per minute (counts/min), due to each of the
four radionuclides in each tissue sample, and in the four reference blood samples, was performed
by a Beckman 8000 -spectrophotometer. The blood flow in each tissue sample was calculated
according to the following proportion:
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The blood flow values determined for each sample were divided by the weight of that sample to
provide a value for tissue perfusion expressed in ml/min/g. Total flow (cardiac output) was also
determined by the microsphere technique using the relationship:

Experimental design
We selected the vasodilator, hydralazine, for this study because (1) it is direct-acting, having
selective action on arterioles; (2) it has a relatively long duration of action; and (3) it is clinically
safe and widely used in human medicine [28, 29]. To study the effect of hydralazine on the
distribution of blood flow between normal and tumor tissue and to relate the flow distribution to
heating, blood flow and temperature of tumor and underlying normal tissue were measured under
four different conditions. First, [141Ce]-labeled microspheres were injected (Trial 1) to measure
the control leve1 of blood flow after blood pressure, core temperature, and tissue temperature
had stabilized following surgery (about 30 min). The tumor-bearing region of one hindlimb was
then heated by passing 13.56 MHz radiofrequency current, generated by a Birtcher diathermy
unit (Birtcher Corporation; El Monte, California, USA), through a set of Helmholtz coils which
encompassed the region.
The arrangement of the coils and tumor-bearing limb is depicted in Fig. 1. The coils were
positioned such that the sites of temperature measurement in tumor and normal tissue were
exposed to approximately the same field strength. To avoid interactions between the thermistors
and the induced magnetic field, we employed a pulsed heating technique. Several heating
episodes lasting 1-5 min each were used to bring the temperature of the normal tissue to a
steady-state target level of approximately 40°C. Tissue temperatures were only monitored during
the short period (approximately 1 min) between heating episodes when the radiofrequency
current was turned off. The thermistors were removed from the cannulae during radiofrequency
heating to prevent current concentration near the tip of such a conductive implant, which may
have caused tissue damage as wel1 as self-heating of, and possible damage to, the thermistors
[30]. [85Sr]-labeled microspheres were injected (Trial 2) when the target temperature had been
maintained for at least 10 min to determine the effect of heating alone on the distribution of
perfusion.
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Fig. 1. Schematic diagram depicting the orientation of the Helmholtz coils with respect
to the tumor-bearing limb. Sites 1 and 2 indicate the positions of cannulae in the tumor
and underlying muscle for insertion of hypodermic-style thermistors.
As the temperatures of the tumor and surrounding normal tissue returned to baseline values,
hydralazine was injected intravenously (0.5 mg per kg body weight). Arterial blood pressure was
monitored to determine the onset of drug effect (tachycardia and increased pulse pressure). When
the effect of the drug on pulsatile blood pressure had stabilized (approximately 15 min), [ 95Nb]labeled microspheres were injected (Trial 3) to determine the change in distribution of perfusion
due to hydralazine alone.
Finally, the tumor-bearing region was heated as before in the presence of hydralazine effect. The
position of the Helmholtz coils and the sites of temperature measurement remained unchanged.
A steady-state temperature of approximately 40°C for the normal tissue again served as a target.
After the target temperature had been maintained for at least 10 min, [46Sc]-labeled microspheres
were injected (Trial 4).
At the end of the experiment, dogs were killed by an injection of saturated KCl solution
(approximately 2 ml) into the left ventricle and tissue samples were excised for weighing and
determination of radioactivity. The Mann-Whitney statistics were calculated for the blood flow
and temperature data for each trial to test the nul1 hypotheses that the blood flow rates and
temperatures of tumor and underlying muscle were the same.
5

RESULTS
Redistribution of blood flow
Figure 2 presents the mean blood flow data for tumor and underlying muscle samples obtained
under the four test conditions previously described. Under normothermic control conditions
(Trial 1) the TVT had a significantly greater leve1 of perfusion than the adjacent muscle (u = 8.0;
P  0.01). After heating alone (Trial 2), tumor and muscle blood flows were not significantly
different. The addition of hydralazine under normothermic conditions (Trial 3) greatly increased
tissue perfusion in the muscle samples to a leve1 5.4 times the control value. At the same time
perfusion of the tumor tissue dropped to about one-half of the control value. These changes were
slightly enhanced by heating. The final observations, after heating (Trial 4), revealed that
perfusion of the normal tissue, rather than being about one-third that of the tumor tissue
(control), had increased to 17 times that of the tumor (u = 1.0; P  0.01).

Fig. 2. Mean blood flow data for tumor and underlying normal muscle obtained during
four different test conditions: normothermic, no drug (Trial 1); hyperthermic, no drug
(Trial 2); normothermic, hydralazine (Trial 3); and hyperthermic, hydralazine
(Trial 4). * Significant at P  0.01; # significant at P  0.05.
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Fig. 3. (A) Intratumor and underlying normal muscle temperatures attained without
hydralazine (Trial 2). (B) Intratumor and underlying normal muscle temperatures
attained after hydralazine treatment (Trial 4).
Temperature data
The complete temperature-time curves for a typical experiment are shown in Fig. 3.
Temperatures attained after local heating for tumor and underlying muscle in al1 8 experiments
are presented in Table 1. When the temperature of the normal tissue was raised to a steady-state
target leve1 of approximately 40 °C before giving hydralazine, the temperature measured in the
tumor was never higher than 42.5 oC and never more than 2.5 o C higher than normal tissue
temperature. In 4 of the 8 dogs it was impossible to raise the temperature of the tumor to a leve1
higher than the normal tissue before hydralazine treatment. When, after the injection of
hydralazine, the temperature of the normal tissue was again raised to a target leve1 of about 40
o
C, tumor temperature rose as high as 51.6 oC. Although the positions of the Helmholtz coils
remained the same, temperature differences between tumor and normal tissue averaging 9.5 oC
(range, 4.5-12.6 oC) were obtained after hydralazine (Table 1). In every animal, hydralazine
treatment permitted dramatic selective heating of the tumor.
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Table 1. Final temperatures (oC) attained after local heating
before and after hydralazine treatment

Table 2. Hemodynamic data (mean  S.E.)
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Hemodynamic data
Table 2 presents cardiac output, blood pressure and total peripheral resistance values obtained at
the times of microsphere injection. At the doses of hydralazine employed, total peripheral
resistance dropped to approximately one-half the control value, mean blood pressure was
significantly less than control, but cardiac output increased by about 50%. Although mean
pressure decreased, perfusion was not compromised after treatment with hydralazine.
DISCUSSION
Pretreatment of TVT-bearing dogs with the direct-acting vasodilator , hydralazine, produced a
highly favorable redistribution of blood flow between normal and tumor tissue, making possible
selective heating of the tumors to therapeutic temperatures. Although the present protocol is
limited in that only one tumor model was studied, this particular model provided a rigorous test
of the specific therapeutic effect of hydralazine. Prior to hydralazine treatment normal muscle
blood flow was no greater--and usually much less--than tumor blood flow, making selective
tumor heating impossible. After hydralazine treatment normal muscle blood flow averaged 17
times that in the tumor and an average temperature difference of 9.5 o C was observed.
Dickson and Calderwood’s [8] compendium of single-treatment thermal death times for various
human and animal tumors can be summarized using the simple expression,

where T = tumor temperature ( oC) and t = required exposure time for tumor necrosis (hr) [10].
According to this relationship, for the intratumor temperatures achieved in this study, irreversible
damage could be expected in as little as 4.1 min (at 51.6 °C ) to 42 min (at 45 °C). At the same
time, the increased perfusion of surrounding normal tissue produced by hydralazine kept normal
tissue temperature wel1 below 42 °C.
Selective tumor heating of the magnitude achieved in this study has rarely been described.
However, when comparable heating is achieved clinically the results are encouraging. Storm
reported that in more than three-quarters of the human tumors in which temperatures of 42-50 °C
were achieved by radiofrequency heating, minima1 normal tissue injury was sustained, while
moderate to marked necrosis occurred in successfully heated tumors [1]. LeVeen et al. showed
that radiofrequency therapy producing a mean intratumor temperature of 48.4 °C in seven
patients consistently caused necrosis of cancerous tissue with little destruction of normal tissue
[3]. It is likely, therefore, that treatment with a vasodilator drug prior to local hyperthermia
therapy will increase the number of tumors which can be selectively heated while decreasing the
incidence of normal tissue damage.
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The therapeutic effect of hydralazine observed in this study was obtained at doses that did not
depress blood pressure unacceptably. Although the drug decreased peripheral resistance by about
one-half, blood pressure was maintained at reasonable levels by the reactive increase in cardiac
output (Table 2). These effects are expected for a direct-acting vasodilator and appear to be
within clinically reasonable limits.
Ideally, cancer therapy should destroy neoplastic cells without injuring nearby normal cells, just
as modern antibiotics destroy bacteria without damaging the host. Unfortunately, the chemical
differences between cancer cells and normal cells are relatively subtle. However, we believe
there are crucial anatomic and functional differences between tumor blood vessels and normal
blood vessels, which make the whole tumor, as opposed to individual tumor cells, selectively
vulnerable to local hyperthermia. The results of this study show that it is possible to treat a tumor
as a specific ‘organ’ which responds to a drug in a qualitatively different manner than normal
organs.
For the TVT system, the difference in response to hydralazine was unequivocal: blood flow to
normal tissue increased; blood flow to tumor tissue decreased. This functional difference is
rationally related to well-reported anatomic differences between blood vessels in tumor and
normal tissues; specifically, the lack of smooth muscle in the walls of tumor vessels [16, 17, 18].
This selective response was easily exploited to produce selective heating of the tumor. As local
hyperthermia techniques improve, adjuvant treatment with vasodilators is likely to increase the
intratumor temperatures that can be safely attained and decrease the severity of thermal damage
to surrounding normal tissues.
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